Biophytis S.A. Asset Resilience Ratio
Biophytis S.A. asset resilience ratio. Biophytis S.A. (BPTSY) has an Asset Resilience Ratio of 1.30% as of June 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See BPTSY cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Biophytis S.A. (2012–2023)
Asset resilience ratio of Biophytis S.A. from 2012 to 2023. This chart shows how Biophytis S.A.'s Asset Resilience Ratio has changed over time. Read how much debt does Biophytis S.A. carry for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Biophytis S.A.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Biophytis S.A. asset portfolio.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $113.00K | 1.3% |
| Total Liquid Assets | $113.00K | 1.30% |
Asset Resilience Insights
- Limited Liquidity: Biophytis S.A. maintains only 1.30% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Biophytis S.A. Industry Peers by Asset Resilience Ratio
Compare Biophytis S.A.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL |
Biotechnology | 1.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA |
Biotechnology | 53.11% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381 |
Biotechnology | 4.98% |
Biophytis S.A. Asset Resilience Ratio by Year (2012–2023)
Biophytis S.A. asset resilience ratio by year from 2012 to 2023. The table below shows the annual Asset Resilience Ratio data for Biophytis S.A..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | 3.08% | $368.00K | $11.96 Million | +0.39pp |
| 2022-12-31 | 2.68% | $590.00K | $21.99 Million | -0.71pp |
| 2021-12-31 | 3.39% | $1.23 Million | $36.26 Million | -44.11pp |
| 2020-12-31 | 47.50% | $12.92 Million | $27.21 Million | +44.81pp |
| 2019-12-31 | 2.69% | $475.00K | $17.67 Million | -20.18pp |
| 2018-12-31 | 22.87% | $5.00 Million | $21.86 Million | -15.67pp |
| 2017-12-31 | 38.54% | $10.00 Million | $25.95 Million | +38.54pp |
| 2015-12-31 | 0.00% | $367.00 | $13.52 Million | -24.83pp |
| 2012-12-31 | 24.84% | $300.49K | $1.21 Million | -- |
About Biophytis S.A.
Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases. Its therapeutics targets and activates key biological resilience pathways that can protect against and counteract the effects of the multiple biological and environmental stresses, … Read more